LTBP-2 confers pleiotropic suppression and promotes dormancy in a growth factor permissive microenvironment in nasopharyngeal carcinoma

Cancer Letters

Volumn 325, Issue 1, 2012, Pages 89-98

  Chen, Han ^a   Ko, Josephine Mun Yee ^b   Wong, Victor Chun Lam ^b   Hyytiainen, Marko ^c   Keski Oja, Jorma ^c   Chua, Daniel ^b,d   Nicholls, John M ^b   Cheung, Florence Man Fung ^b,e   Lee, Anne Wing Mui ^b,e   Kwong, Dora Lai wan ^b   Chiu, Pui Man ^b   Zabarovsky, Eugene R ^f,g,h   Tsao, Sai Wah ^b   Tao, Qian ⁱ   Kan, Rebecca ^b   Chan, Stephen Ho Kin ^b   Stanbridge, Eric J ^j   Lung, Maria Li ^b  

^a HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Hong Kong)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^d HONG KONG SANATORIUM AND HOSPITAL   (Hong Kong)

^e PAMELA YOUDE NETHERSOLE EASTERN HOSPITAL   (Hong Kong)

^f KAROLINSKA INSTITUTE   (Sweden)

^g ENGELHARDT INSTITUTE OF MOLECULAR BIOLOGY   (Russian Federation)

^h LINKÖPING UNIVERSITY   (Sweden)

ⁱ CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^j UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

Anti angiogenesis; Latent transforming growth factor binding protein 2 (LTBP 2); Metastatic growth; Nasopharyngeal carcinoma (NPC); Tumor cell dormancy; Tumor suppression

Indexed keywords

DNA; GROWTH FACTOR; LATENT TRANSFORMING GROWTH FACTOR BINDING PROTEIN 2; TETRACYCLINE; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CARCINOGENICITY; CELL CULTURE; CELL MIGRATION; COLONY FORMATION; CONTROLLED STUDY; DNA METHYLATION; DORMANCY; FEMALE; GENE EXPRESSION SYSTEM; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; MOUSE; NASOPHARYNX CARCINOMA; NONHUMAN; PLEIOTROPY; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SECRETION; TUMOR BIOPSY; TUMOR MICROENVIRONMENT;

AZACITIDINE; CELL LINE, TUMOR; CELL MOVEMENT; CELL TRANSFORMATION, NEOPLASTIC; DNA METHYLATION; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYDROXAMIC ACIDS; LATENT TGF-BETA BINDING PROTEINS; NASOPHARYNGEAL NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PROMOTER REGIONS, GENETIC; TUMOR MICROENVIRONMENT; TUMOR SUPPRESSOR PROTEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84865283257     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2012.06.005     Document Type: Article

References (39)

1. Saharinen J., Hyytiainen M., Taipale J., Keski-Oja J. Latent transforming growth factor-b binding proteins (LTBPs) - structural extracellular matrix proteins for targeting TGF-b action. Cytokine & Growth Factor Reviews 1999, 10:99-117.
2. Oklu R., Hesketh R. The transforming growth factor b binding protein (LTBP) family. Biochem. J. 2000, 352:601-610.
3. Mauel S., Kruse B., Etschmann B., Schulenburg A.G.V.D., Schaerig M., Stovesand K., Wilcken B., Sterner-Kock A. Latent transforming growth factor binding protein 4 (LTBP-4) is downregulated in human mammary adenocarcinomas in vitro and in vivo. APMIS 2007, 115:687-700.
4. Chan S.H., Ko J.M.Y., Chan K.W., Chan Y.P., Tao Q., Hyytiainen M., Keski-Oja J., Law S., Srivastava G., Tang J., Tsao S.W., Chen H., Stanbridge E.J., Lung M.L. The ECM protein LTBP-2 is a suppressor of esophageal squamous cell carcinoma tumor formation but higher tumor expression associates with poor patient outcome. International Journal of Cancer. 2011, 129:565-573.
5. Hyytiainen M., Keski-Oja J. Latent TGF-beta binding protein LTBP-2 decreases fibroblast adhesion to fibronectin. The Journal of Cell Biology 2003, 163:1363-1374.
6. Vehvilainen P., Hyytiainen M., Keski-Oja J. Latent transforming growth factor-beta-binding protein 2 is an adhesion protein for melanoma cells. Journal of Biological Chemistry 2003, 278:24705-24713.
7. Lo K.-W., Teo P.M.L., Hui A.B.-Y., To K.-F., Tsang Y.-S., Chan S.Y.-Y., Mak K.-F., Lee J.C.K., Huang D.P. High resolution allelotype of microdissected primary nasopharyngeal carcinoma. Cancer Research 2000, 60:3348-3353.
8. Glaser R., Zhang H.-Y., Yao K., Zhu H.-C., Wang F.-X., Li G.-Y., Wen D.-S., Li Y.-P. Two epithelial tumor cell lines (HNE-1 and HONE-1) latently infected with epstein-barr virus that were derived from nasopharyngeal carcinomas. Proceedings of the National Academy of Sciences of the United States of America 1989, 86:9524-9528.
9. Teng Z.-P., Ooka T., Huang D.P., Zeng Y. Detection of epstein-barr virus DNA in well and poorly differentiated nasopharyngeal carcinoma cell lines. Virus Genes 1996, 13:53-60.
10. Huang D.P., Ho J.H., Poon Y.F., Chew E.C., Saw D., Lui M., Li C.L., Mak L.S., Lai S.H., Lau W.H. Establishment of a cell line (NPC/HK1) from a differentiated squamous carcinoma of the nasopharynx. International Journal of Cancer. 1980, 26:127-132.
11. Cheung S.T., Huang D.P., Hui A.B.Y., Lo K.W., Ko C.W., Tsang Y.S., Wong N., Whitney B.M., Lee J.C.K. Nasopharyngeal carcinoma cell line (C666-1) consistently harbouring epstein-barr virus. International Journal of Cancer. 1999, 83:121-126.
12. Protopopov A.I., Li J., Winberg G., Gizatullin R.Z., Kashuba V.I., Klein G., Zabarovsky E.R. Human cell lines engineered for tetracycline-regulated expression of tumor suppressor candidate genes from a frequently affected chromosomal region, 3p21. The Journal of Gene Medicine 2002, 4:397-406.
13. Tsao S.W., Wang X., Liu Y., Cheung Y.C., Feng H., Zheng Z., Wong N., Yuen P.W., Lo A.K.F., Wong Y.C., Huang D.P. Establishment of two immortalized nasopharyngeal epithelial cell lines using SV40 large T and HPV16/E6/E7 viral oncogenes. Biochimica et Biophysica Acta 2002, 1590:150-158.
14. Li H.M., Man C., Jin Y., Deng W., Yip Y.L., Feng H.C., Cheung Y.C., Lo K.W., Meltzer P.S., Wu Z.G., Kwong Y.L., Yuen A.P., Tsao S.W. Molecular and cytogenetic changes involved in the immortalization of nasopharyngeal epithelial cells by telomerase. International Journal of Cancer 2006, 119:1567-1576.
15. Lung H.L., Cheung A.K., Xie D., Cheng Y., Kwong F.M., Murakami Y., Guan X.Y., Sham J.S., Chua D., Protopopov A.I., Zabarovsky E.R., Tsao S.W., Stanbridge E.J., Lung M.L. TSLC1 is a tumor suppressor gene associated with metastasis in nasopharyngeal carcinoma. Cancer Research 2006, 66:9385-9392.
16. Lung H.L., Lo P.H., Xie D., Apte S.S., Cheung A.K., Cheng Y., Law E.W., Chua D., Zeng Y.X., Tsao S.W., Stanbridge E.J., Lung M.L. Characterization of a novel epigenetically-silenced, growth-suppressive gene, ADAMTS9, and its association with lymph node metastases in nasopharyngeal carcinoma. International Journal of Cancer. 2008, 123:401-408.
17. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001, 25:402-408.
18. Lung H.L., Bangarusamy D.K., Xie D., Cheung A.K., Cheng Y., Kumaran M.K., Miller L., Liu E.T., Guan X.Y., Sham J.S., Fang Y., Li L., Wang N., Protopopov A.I., Zabarovsky E.R., Tsao S.W., Stanbridge E.J., Lung M.L. THY1 is a candidate tumour suppressor gene with decreased expression in metastatic nasopharyngeal carcinoma. Oncogene 2005, 24:6525-6532.
19. Ko J.M., Chan P.L., Yau W.L., Chan H.K., Chan K.C., Yu Z.Y., Kwong F.M., Miller L.D., Liu E.T., Yang L.C., Lo P.H., Stanbridge E.J., Tang J.C., Srivastava G., Tsao S.W., Law S., Lung M.L. Monochromosome transfer and microarray analysis identify a critical tumor-suppressive region mapping to chromosome 13q14 and THSD1 in esophageal carcinoma. Molecular Cancer Research: MCR 2008, 6:592-603.
20. Wong V.C., Chen H., Ko J.M., Chan K.W., Chan Y.P., Law S., Chua D., Kwong D.L., Lung H.L., Srivastava G., Tang J.C., Tsao S.W., Zabarovsky E.R., Stanbridge E.J., Lung M.L. Tumor suppressor dual-specificity phosphatase 6 (DUSP6) impairs cell invasion and epithelial-mesenchymal transition (EMT)-associated phenotype. International Journal of Cancer. 2012, 130:83-95.
21. Lo P.H., Lung H.L., Cheung A.K., Apte S.S., Chan K.W., Kwong F.M., Ko J.M., Cheng Y., Law S., Srivastava G., Zabarovsky E.R., Tsao S.W., Tang J.C., Stanbridge E.J., Lung M.L. Extracellular protease ADAMTS9 suppresses esophageal and nasopharyngeal carcinoma tumor formation by inhibiting angiogenesis. Cancer Research 2010, 70:5567-5576.
22. Guo H., Ingolia N.T., Weissman J.S., Bartel D.P. Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature 2010, 466:835-840.
23. Wu Q., Jin H., Yang Z., Luo G., Lu Y., Li K., Ren G., Su T., Pan Y., Feng B., Xue Z., Wang X., Fu D. MiR-150 promotes gastric cancer proliferation by negatively regulating the pro-apoptotic gene EGR2. Biochemical and Biophysical Research Communications 2010, 392:340-345.
24. Jones P.A., Baylin S.B. The epigenomics of cancer. Cell 2007, 128:683-692.
25. Shenker N., Flanagan J.M. Intragenic DNA methylation: implications of this epigenetic mechanism for cancer research. British Journal of Cancer 2012, 106:248-253.
26. Lv X., Xiang Y.Q., Cao S.M., Qian C.N., Li N.W., Guo L., Mai H.Q., Chen Q.Y., Huang P.Y., Luo D., Cao K.J., Hong M.H., Guo X. Prospective validation of the prognostic value of elevated serum vascular endothelial growth factor in patients with nasopharyngeal carcinoma: more distant metastases and shorter overall survival after treatment. Head & Neck 2010, 33:780-785.
27. Pantel K., Schlimok G., Braun S., Kutter D., Lindemann F., Schaller G., Funke I., Izbicki J.R., Riethmuller G. Differential expression of proliferation-associated molecules in individual micrometastatic carcinoma cells. Journal of the National Cancer Institute 1993, 85:1419-1424.
28. Demicheli R., valagussa P., Bonadonna G. Does surgery modify growth kinetics of breast cancer micrometastases?. British Journal of Cancer 2001, 85:490-492.
29. Braun S., Vogl F.D., Naume B., Janni W., Osborne M.P., Coombes R.C., Schlimok G., Diel I.J., Gerber B., Gebauer G., Pierga J.-Y., Marth C., Oruzio D., Wiedswang G., Solomayer E.-F., Kundt G., Strobl B., Fehm T., Wong G.Y.C., Bliss J., Vincent-Salomon A., Pantel K. A pooled analysis of bone marrow micrometastasis in breast cancer. New England Journal of Medicine 2005, 353:793-802.
30. Goldberg S., Harms J.F., Quon K., Welch D.R. Metastasis-suppressed C8161 melanoma cells arrest in lung but fail to proliferate. Clinical & Experimental Metastasis 1999, 17:601-607.
31. Pantel K., Alix-Panabieres C., Riethdorf S. Cancer micrometastases. Nature reviews. Clinical Oncology 2009, 6:339-351.
32. Naumov G.N., MacDonald I.C., Weinmeister P.M., Kerkvliet N., Nadkarni K.V., Wilson S.M., Morris V.L., Groom A.C., Chambers A.F. Persistence of solitary mammary carcinoma cells in a secondary site: a possible contributor to dormancy. Cancer Research 2002, 62:2162-2168.
33. Paget S. The distribution of secondary growths in cancer of the breast. Cancer Metastasis Reviews 1989, 8:98-101.
34. Bissell M.J., Radisky D.C., Rizki A., Weaver V.M., Petersen O.W. The organizing principle: microenvironmental influences in the normal and malignant breast. Differentiation; Research in Biological Diversity 2002, 70:537-546.
35. Barkan D., Green J.E., Chambers A.F. Extracellular matrix: a gatekeeper in the transition from dormancy to metastatic growth. European Journal of Cancer 2010, 46:1181-1188.
36. Kren A., Baeriswyl V., Lehembre F., Wunderlin C., Strittmatter K., Antoniadis H., Fassler R., Cavallaro U., Christofori G. Increased tumor cell dissemination and cellular senescence in the absence of beta1-integrin function. The EMBO Journal 2007, 26:2832-2842.
37. Barkan D., Kleinman H., Simmons J.L., Asmussen H., Kamaraju A.K., Hoenorhoff M.J., Liu Z.Y., Costes S.V., Cho E.H., Lockett S., Khanna C., Chambers A.F., Green J.E. Inhibition of metastatic outgrowth from single dormant tumor cells by targeting the cytoskeleton. Cancer Research 2008, 68:6241-6250.
38. Hirani R., Hanssen E., Gibson M.A. LTBP-2 specifically interacts with the amino-terminal region of fibrillin-1 and competes with LTBP-1 for binding to this microfibrillar protein. Matrix Biology: Journal of the International Society for Matrix Biology 2007, 26:213-223.
39. Parsi M.K., Adams J.R., Whitelock J., Gibson M.A. LTBP-2 has multiple heparin/heparan sulfate binding sites. Matrix Biology: Journal of the International Society for Matrix Biology 2010, 29:393-401.